Top Ten most popular articles on Pharmafile.com this week
pharmafile | July 6, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AbbVie, Astrazenaca, Donald Trump, Pfizer, pharma, top ten
As the first week of July comes to an end we take a look over the most popular stories of the previous seven days.
While a series of scandals have drawn some of the big names into a web of legal issues, this week has offered a glimpse of hope as progress is made in innovative new treatments.
Our top story focuses on the legal action being undertaken by the State of Massachusetts against those responsible for marketing Purdue Pharma’s OxyContin. However as Trump lashes out against big pharma we discuss the exciting discoveries being made in the fight against Parkinson’s and HIV.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. AbbVie ordered to pay $448m over generic delays
A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham litigation in an effort to delay generic versions of the testosterone replacement drug AndroGel from getting to market.
9. AstraZeneca chalks up double Japanese approval in lung and breast cancer
It’s a big step forward for AstraZeneca’s global marketing operations as the company announced that two of its products have received approval in Japan in the treatment of two key cancers.
8. Unfazed by Trump, Pfizer hikes prices for 100 of its drugs
Despite threats from President Trump, Pfizer has just hefted the price of 40 of its drugs in its second round of hikessince the beginning of the year. The US firm has bolstered the price tags of around 100 of its products this year.
7. Novartis spins off Alcon as CEO focuses drug search
Novartis has announced a plan to spinoff Alcon – its eye care division – into a separately-traded standalone company.
6. NICE turns down Roche’s Ocrevus in early primary progressive multiple sclerosis
Roche’s sometimes strained relationship with NICE continues as the health watchdog for England and Wales chose to reject the former’s humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab) in the treatment of early primary progressive multiple sclerosis (MS).
5. Cadila scores FDA approval for BMS and Alvogen generics
Cadila Healthcare has announced that it has gained FDA final approval to market Nifedipine ER tablets and cholestyramine oral suspension.
4. Promising new drug slows Parkinson’s progression in mice
The drug, which is similar to compounds used to treat diabetes, could be one of the first treatments to directly target the progression of the degenerative condition.
3. EMA approves Cimzia for use in treating plaque psoriasis
The Brussels-based pharmaceutical company UCB has announced that the European Medicines Agency (EMA) has approved a label extension for Cimzia (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis.
2. Abivax drug lowers HIV DNA in blood and tissue, but has the opposite effect for some
Biotechnology firm Abivax has lifted the curtain on new Phase 2a data for its HIV therapy ABX464, showing that the drug was able to reduce levels of the virus’ DNA in blood and rectal tissue.Top of Form
1. GSK Director indicted in Massachusetts opioid lawsuit
The state of Massachusetts has taken action to sue a board member at GlaxoSmithKline for her alleged role in fuelling the opioid addiction crisis that has devastated the United States in recent years.
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
